
About Us
Samyang Biopharm USA, Inc is the new subsidiary of Samyang Biopharmaceuticals Corporation (Korea) and will focus on biologics development in oncology and rare disease. The company will seek late preclinical to Phase 1 antibody, antibody drug conjugate, and recombinant proteins for global in-licensing to develop in the United States.
You may find a link to Samyang Holdings Corporation (Korea) here